

## COMPANY OVERVIEW

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company seeking to discover and develop novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. We employ unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. These technologies are designed to efficiently deliver small molecule therapeutics that are safe, effective and convenient to administer. We have identified promising preclinical and clinical-stage antiviral therapeutics that target the replication process of influenza virus, norovirus, coronavirus and hepatitis C virus.

## RECENT NEWS

### **Cocrystal Pharma's First Oral Norovirus Protease Inhibitor CDI-988 to be Featured at the International Society for Antiviral Research Conference (ICAR) 2026**

Feb 19 2026, 8:00 AM EST

### **Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus**

Dec 18 2025, 8:00 AM EST

### **Cocrystal Pharma to Present at the Noble Capital Markets' 21st Emerging Growth Equity Conference**

Dec 1 2025, 8:00 AM EST

## STOCK OVERVIEW

Symbol	COCP
Exchange	Nasdaq
Market Cap	13.92m
Last Price	\$1.01
52-Week Range	\$0.8588 - \$2.67

03/06/2026 09:00 PM EST

## INVESTOR RELATIONS

Alliance Advisors IR  
Jody Cain  
T: 310-691-7100  
[Jcain@allianceadvisors.com](mailto:Jcain@allianceadvisors.com)

## MANAGEMENT TEAM

### **Sam Lee, Ph.D.**

Co-Chief Executive Officer and President

### **James J. Martin**

Co-Chief Executive Officer and Chief Financial Officer

## COCRYSTAL PHARMA, INC.

19805 North Creek Parkway  
Bothell, WA 98011  
US

## DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.